A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Lomtegovimab (Primary) ; Lomtegovimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
Most Recent Events
- 03 Oct 2024 Status changed from completed to discontinued due to change in viral variant epidemiology.
- 05 Oct 2021 Status changed from active, no longer recruiting to completed.
- 02 Aug 2021 Planned End Date changed from 15 Sep 2021 to 21 Dec 2021.